Sysmex (OTCMKTS:SSMXY) Shares Gap Down - Time to Sell?

Key Points

• Sysmex Corporation shares gapped down from $12.60 to open at $12.00, closing the day at $12.44.
• Analysts have upgraded Sysmex's rating from a "strong sell" to a "hold," indicating a more favorable outlook.
• The company reported earnings of $0.05 per share, falling short of the consensus estimate of $0.12, with revenue also missing expectations at $717.09 million.

Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report) shares gapped down before the market opened on Wednesday . The stock had previously closed at $12.60, but opened at $12.00. Sysmex shares last traded at $12.44, with a volume of 754 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded Sysmex from a "strong sell" rating to a "hold" rating in a research report on Thursday, August 14th. One analyst has rated the stock with a Hold rating, According to MarketBeat, the company presently has an average rating of "Hold".

Sysmex Stock Down 1.5%

The company has a debt-to-equity ratio of 0.12, a current ratio of 3.37 and a quick ratio of 2.49. The stock has a market capitalization of $7.81 billion, a PE ratio of 24.83 and a beta of 1.10. The company has a 50 day moving average price of $14.22 and a 200-day moving average price of $16.55.

Sysmex (OTCMKTS:SSMXY - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.07). Sysmex had a net margin of 9.35% and a return on equity of 10.20%. The firm had revenue of $717.09 million for the quarter, compared to the consensus estimate of $807.27 million. As a group, analysts forecast that Sysmex Corporation ADR will post 0.57 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.